RNTX (Rein Therapeutics) Interest Coverage : No Debt ⁽¹⁾ (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Rein Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Rein Therapeutics's Operating Income for the three months ended in Mar. 2025 was $-5.61 Mil. Rein Therapeutics's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. Rein Therapeutics has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Rein Therapeutics Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Rein Therapeutics's Interest Coverage or its related term are showing as below:

RNTX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

RNTX's Interest Coverage is ranked better than
98.67% of 377 companies
in the Biotechnology industry
Industry Median: 119.89 vs RNTX: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rein Therapeutics Interest Coverage Historical Data

The historical data trend for Rein Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Rein Therapeutics Interest Coverage Chart

Rein Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

Get a 7-Day Free Trial

N/A

No Debt

Rein Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Coverage	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Rein Therapeutics's Interest Coverage

For the Biotechnology subindustry, Rein Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rein Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Rein Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rein Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Rein Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-28.11 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Rein Therapeutics had no debt ⁽¹⁾.

Rein Therapeutics's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Rein Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-5.61 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Rein Therapeutics had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Rein Therapeutics (NAS:RNTX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Rein Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Rein Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Rein Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rein Therapeutics Inc (NAS:RNTX) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758

Website

https://www.reintx.com

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Executives

James Brian Windsor	officer: See Remarks	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey	director	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso	director	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler	officer: See Remarks	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter	10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros	director	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H	director	C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic	officer: SVP, Chief Medical Officer	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory	officer: SVP, Chief Business Officer	305 THAYER POND ROAD, WILTON CT 06897
William Mckee	director
Nolan Howard Sigal	director	941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall	officer: VP, Finance and Operations	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd	officer: President and CEO	10445 PACIFIC CENTER CT, SAN DIEGO CA 92121